Immune Checkpoint Inhibitors in NSCLC
Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the variety of immune checkpoint inhibitors that are currently being explored as treatments for patients with non-small cell lung cancer (NSCLC).
Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the variety of immune checkpoint inhibitors that are currently being explored as treatments for patients with non-small cell lung cancer (NSCLC).
Clinical Pearls:
- Several therapies are being explored in NSCLC that target immune checkpoints, including PD-1 inhibitors nivolumab and MK-3475, and the PD-L1 inhibitor MPDL3280A
- Since these agents have been explored primarily in phase I studies, it remains unclear whether targeting PD-1 or PD-L1 is superior
- At this point, it appears that PD-L1 inhibition could result in fewer side effects, like pneumonitis
- Future research in this space will focus on selecting patients, minimizing toxicities, and determining which class of agents is most effective
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
